ZBH

Zimmer Biomet Holdings has been building out its orthopedic surgery technology, yet the share price is still shaped by a long, uneven return profile that raises a simple question about value.

ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.

The Comeback Club connects people who have had joint replacement with those considering it. ATLANTA and WARSAW, Ind., Oct.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and (SIX: ZBH), a global medical technology leader, today announced the launch of ROSA® Knee with OptimiZe™ in India, an enhanced version of its ROSA® Knee System designed to support personalized robotic-assisted total…

Zimmer Biomet is expected to release its third-quarter earnings next month, and analysts anticipate a marginal rise in its bottom line.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including Zimmer Biomet (NYSE:ZBH) and its peers.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks.

The article explains when custody modification may be appropriate as family circumstances and a child's needs change. READING, Pa., Oct. 6, 2026 /PRNewswire/ -- What allows a Pennsylvania custody order to be changed?

Zimmer Biomet currently trades at $91.50 per share and has shown little upside over the past six months, posting a middling return of 4.4%. The stock also fell short of the S&P 500’s 16.9% gain during that period.